NCT02609789View on ClinicalTrials.gov

A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions
Systemic Lupus ErythematosusHealthy
Interventions
DRUG

JNJ-55920839

JNJ-55920839 will be administered as either IV infusion or subcutaneous injection.

DRUG

Placebo

0.9 percent (%) normal saline.

Trial Locations (16)

Unknown

Birmingham

Rochester

Durham

Leuven

Merksem

Chisinau

Otwock

Szczecin

Bucharest

Timișoara

Barcelona

Madrid

Santiago de Compostela

Seville

Kaohsiung City

Taichung

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02609789 - A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter